Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
fda
life sciences
national blog main
raleigh-durham blog main
raleigh-durham top stories
10
×
boston blog main
clinical trials
indiana blog main
indiana top stories
national top stories
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
amgen
cancer
teva pharmaceutical
drugs
johnson & johnson
medical device
migraine research foundation
novartis
startups
abbvie
What
fda
10
×
drug
won
approval
bio
new
roundup
drugs
migraine
approved
class
companies
decades
developed
friday
medicines
news
oral
activity
acute
addresses
agency
ahead
aimmune
allergy
amgen
approvals
arguments
asco
august
awarded
big
biogen
biotech
branded
busy
cancer
candidates
cash
causes
Language
unset
Current search:
biotech
×
" raleigh-durham top stories "
×
fda
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines